SCHEDULE 13G: CVI Investments, Heights Capital Disclose 9.9% Citius Stake

CVI Investments, Inc. and its investment manager, Heights Capital Management, Inc., have disclosed a 9.9% beneficial ownership stake in Citius Pharmaceuticals, Inc.

Summary

• CVI Investments, Inc. and Heights Capital Management, Inc. jointly reported beneficial ownership of 1,655,681 shares of Citius Pharmaceuticals, Inc. common stock.
• This represents 9.9% of the outstanding common stock of Citius Pharmaceuticals, Inc.
• The ownership includes 1,460,000 shares and additional shares issuable upon the exercise of pre-funded and other warrants.
• Warrants are subject to a blocker provision, preventing exercise if beneficial ownership would exceed 9.99%.
• Heights Capital Management, Inc. acts as the investment manager for CVI Investments, Inc., exercising shared voting and dispositive power over the reported shares.
• The filing date is October 27, 2025, with the event date requiring the filing being October 20, 2025.

Sentiment

Score: 6

Explanation: The filing is a neutral disclosure of beneficial ownership. The presence of a significant institutional investor like CVI Investments and Heights Capital Management can be viewed as a positive signal of confidence in Citius Pharmaceuticals, Inc., but the filing itself contains no operational or financial news.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Citius Pharmaceuticals, Inc.'s operations or financial performance.

Management Comments

• To the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing indicates a significant institutional investment in Citius Pharmaceuticals, Inc., a company likely operating in the biotechnology or pharmaceutical sector given its name. Such disclosures are routine for passive investors crossing the 5% ownership threshold and provide transparency on major shareholder positions, which can be a signal of investor confidence or strategic interest within the industry.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant institutional ownership. The presence of a large institutional investor may influence market perception and trading activity.
• Company Management: Awareness of a significant passive investor holding a substantial stake, potentially influencing strategic decisions or future capital needs if warrants are exercised.

Key Dates

Recommendation

This Schedule 13G filing primarily serves as a disclosure of a significant passive ownership stake by institutional investors. While the presence of CVI Investments and Heights Capital Management holding 9.9% of Citius Pharmaceuticals could be seen as a positive signal of institutional confidence, the filing itself does not contain new operational, financial, or strategic information that would warrant a 'buy' or 'sell' recommendation. It's a routine transparency filing. Investors should 'hold' and await further fundamental news or financial results from Citius Pharmaceuticals to make a more informed decision.

Keywords

Citius Pharmaceuticals, CVI Investments, Heights Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, Biotechnology, Pharmaceuticals